MXCT Insider Trading

Insider Ownership Percentage: 1.22%
Insider Buying (Last 12 Months): GBX 0
Insider Selling (Last 12 Months): £23,522.40

MaxCyte Insider Trading History Chart

This chart shows the insider buying and selling history at MaxCyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MaxCyte Share Price & Price History

Current Price: GBX 380
Price Change: +0.30 (1.20%)
As of 06/14/2024 01:00 AM ET

This chart shows the closing price history over time for MXCT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

MaxCyte Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2024John JohnstonInsiderSell5,000GBX 441£22,050
11/27/2023John JohnstonInsiderSell200GBX 453£906
7/26/2023John JohnstonInsiderSell118GBX 480£566.40
6/14/2023Doug DoerflerInsiderSell28,883GBX 504£145,570.32
4/12/2023Doug DoerflerInsiderSell60,000GBX 502£301,200
11/22/2021Richard DouglasInsiderBuy20,000GBX 1,112£222,400
See Full Table

SEC Filings (Institutional Ownership Changes) for MaxCyte (LON:MXCT)

75.03% of MaxCyte stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

MaxCyte logo
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Read More on MaxCyte

Today's Range

Now: GBX 380
Low: 377.60
High: 388

50 Day Range

MA: GBX 343.41
Low: 290
High: 400

52 Week Range

Now: GBX 380
Low: 180
High: 430

Volume

3,706 shs

Average Volume

30,201 shs

Market Capitalization

£397.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Who are the company insiders with the largest holdings of MaxCyte?

MaxCyte's top insider investors include:
  1. Doug Doerfler (Insider)
  2. John Johnston (Insider)
Learn More about top insider investors at MaxCyte.